Association between hepatosteatosis and severity of COVID-19 pneumonia: a CT-based study

Year 2025, Volume: 16 Issue: 56 , 148 - 154 , 16.12.2025

Esra Soyer Güldoğan , Serra Özbal , Yeliz Aktürk , İrfan Şencan , Baki Hekimoğlu

https://doi.org/10.17944/interdiscip.1698641

https://izlik.org/JA24PL67HJ

Abstract

Objective: Recent studies show that comorbidities are a risk factor for coronavirus disease 2019 (COVID-19) pneumonia. We aimed to evaluate whether hepatosteatosis (HS) plays a role in predicting the severity of the disease.
Method: We included 505 patients whose real-time polymerase chain reaction tests were positive and who had a thoracic computed tomography (CT) scan. Age, gender, height-weight, and comorbidities of the patients were noted. Three radiologists re-evaluated thoracic CTs, and the severity score (between 20-40 was considered a severe disease) was determined. Liver and spleen densities were measured by standardizing, the liver-spleen density ratio was selected, and steatosis was defined as ≤0.8. We used X2 and student t-test, logistic regression, and odds ratio with a 95% confidence interval.
Results: In 149 (29.5%) patients, liver/spleen density ratios favored adiposity. The mean tomography severity score of the patients was 16 (±10.5). When we look at the distribution of 192 (38%) patients with a CT severity score of ≥20; the number of patients over 65 years of age and the male gender were higher. We also found a higher rate of HS in this group compared to the group with a lower CT severity score. When the correlation between the patients’ liver/spleen density ratios and the severity of pneumonia was examined, we observed that the severity of the disease increased significantly as the liver/spleen density ratio decreased (p<0.001).
Conclusion: HS and age were independently related with severe COVID-19 pneumonia. For patients who have viral pneumonia, the liver-spleen density ratio might be measured.

Keywords

Viral pneumonia , liver/spleen density ratio , severity index

References

• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239. DOI:10.1001/jama.2020.2648.
• Mantovani A, Byrne CD, Zheng MH, Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a metaanalysis of observational studies. Nutr Metab Cardiovasc Dis 2020;30:1236–1248. DOI:10.1016/j.numecd.2020.05.014.
• Targher G, Mantovani A, Wang XB, Yan HD, Sun QF, Pan KH, et al. Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab 2020;46(4):335–337. DOI: 10.1016/j.diabet.2020.05.001.
• Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, et al. Nonalcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol. 2020;73(2):451–3. DOI: 10.1016/j.jhep.2020.03.044
• Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005–2023. DOI: 10.1002/hep.25762.
• Zheng K I, Gao F, Wang X B, Sun QF, Pan KH, Wang T Y, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associatedfatty liver disease. Metabolism. 202;108, 154244. DO I:10.1016/j.metabol.2020.154244.
• Targher G, Mantovani A, Byrne CD, Wang XB, Yan HD, Sun QF, et al. Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. Diabetes Metab 2020;46(6):505-507. DOI: 10.1016/j.diabet.2020.06.001
• Targher G, Mantovani A, Byrne CD, Wang X B, Yan HD, Sun QF, et al. (2020). Risk of severe illness from COVID-19 in patients with metabolic dysfunctionassociated fatty liver disease and increased liver stiffness. Gut. 2020; 69(8), 1545–1547. doi: 10.1136/gutjnl-2020-321611.
• Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2005;41(1):82–9. DOI:10.1002/hep.20515
• Zhang YN, Fowler KJ, Hamilton G, Cui JY, Sy EZ, Balanay M, et al. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. Br J Radiol 2018;91:20170959. doi: 10.1259/bjr.20170959.
• Bohte AE, Van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta- analysis. Eur Radiol 2011;21:87–97. doi: 10.1007/s00330-010-1905-5.
• Limanond P, Raman SS, Lassman C, Sayre J, Ghobrial RM, Busuttil RW, et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology. 2004;230:276–280. DOI: 10.1148/radiol.2301021176.
• Wang XJ, Malhi H. Nonalcoholic fatty liver disease. Ann Intern Med 2018;169:ITC65–80. DOI: 10.7326/AITC201811060.
• Rubin GD, Ryerson CJ , Haramati LB, Sverzellati N, Kanne JP, Raoof S, et al. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner Society. Radiology 2020;7:201365. doi:10.1016/j.chest.2020.04.003.
• Li K, Fang Y, Li W, Pan C, Qin P, Zhong Y, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). European radiology 2020;30(8):4407-4416. DOI:10.1007/s00330-020-06817-6.
• Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M, et al. Radiological Society of North America Expert Consensus Statement on reporting chest CT findings related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. Radiology 2020;2:2. DOI:10.1097/RTI.0000000000000524.
• Yang R, Li X, Liu H, Zhen Y, Zhang X, Xiong Q, et al. Chest CT severity score: an imaging tool for assessing severe COVID-19. Radiology 2020;2:2. DOI: 10.1148/ryct.2020200047
• Prokop M, Everdingen W Van, Vellinga T van Rees, Quarles van Ufford H, Stöger L, Beenen L , et al. CO-RADS - a categorical CT assessment scheme for patients with suspected COVID-19: definition and evaluation. Radiology 2020;296:97-104. DOI: 10.1148/radiol.2020201473.
• Byun J, Lee SS, Sung YS, Shin Y, Yun J, Kim HS, et al. CT indices for the diagnosis of hepatic steatosis using non-enhanced CT images: development and validation of diagnostic cut-off values in a large cohort with pathological reference standard. Eur Radiol 2019;29:4427–4435. DOI: 10.1007/s00330-018-5905-1.
• 20. Zhang Y, Wang C, Duanmu Y, Zhang C, Zhao W, Wang L, et al. Comparison of CT and magnetic resonance mDIXON-Quant sequence in the diagnosis of mild hepatic steatosis. Br J Radiol 2018;91:20170587. DOI: 10.1259/bjr.20170587
• World Health Organization, 2. Clinical management of COVID-19: interim guidance, 27 May 2020 (No. WHO/2019-nCoV/clinical/2020.5). World Health Organization.
• Liu W, Tao ZW, Wang L,Yuan ML, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chinese medical journal 2020;133(09):1032-1038. DOI: 10.1097/CM9.0000000000000775.
• Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;27;323(13):1061-1069. doi:10.1001/jama.2020.1585.
• Wang L, Lin ZQ, Wong A. COVID-Net: A Tailored Deep Convolutional Neural Network Design for Detection of COVID-19 Cases from Chest Radiography Images. Scientific Reports 2020:11;10(1):19549. doi.org/10.1038/s41598-020-76550-z
• 25. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020:26;382(13):1708-1720. DOI: 10.1056/NEJMoa2002032.
• Palomar-Lever A, Barraza G, Galicia-Alba J, Echeverri-Bolaños M, Escarria-Panesso R, Padua-Barrios J, et al. Hepatic steatosis as an independent risk factor for severe disease in patients with COVID-19: A computed tomography study. JGH Open 2020:4;4(6):1102-1107. DOI: 10.1002/jgh3.12395.
• Singh S, Khan A . Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study. Gastroenterology 2020: 159(2):768-771. doi: 10.1053/j.gastro.2020.04.064.
• Zheng KI, Gao F, Wang XB, Sun QF, Pan KH, Wang TY, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;108:154244. doi:10.1016/j.metabol.2020.154244